FAS and metabolic dysfunction-associated steatotic liver disease: Additional studies using in vitro models evidenced the synergistic benefits against NAFLD by combining ChiA with omega-3 fatty acids, achieving a tune regulation of AMPK-mediated PPARα/UCP-2 SREBP-1/FAS pathways [47].